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consecutive patients in stable clinical condition and with lesions
amenable to be treated with the BVS stent according to predeﬁned
criteria. Patients were randomized to either treatment with BVS or
Synergy. The procedure was performed according to operators
discretion. Full details of the procedure were collected including use
of resources, devices, radiation, contrast and myocardial enzymes and
creatinine before and after procedure.
RESULTS A total of 100 patients (124 lesions) were included with no
signiﬁcant differences in baseline characteristics and only a trend to
have more lesions treated in the Synergy group. Pre-dilatation was
more frequent with BVS (97% vs. 24%;p<0.001). Implanted stents had
similar diameter (30.4 mm in BVS and 30.5 mm in Synergy) and
length (196 mm in BVS and 208 mm in Synergy). Post-dilatation
was more frequently done with BVS (58% vs. 42%:p¼0.1) using very
similar balloons (3.3 mm diameter in both groups) and peak pressure
(16 atm and 15 atm respectively). The number of wires and catheters
was equivalent. The BVS group showed an increase in use of contrast
volume of 10%, increase in radiation of 28% and an increase in the 24
h post-PCI TnI value a 53% higher in comparison with the Synergy
group. No cases of contrast-induced nephropathy were noted.
CONCLUSIONS The use of current generation of BVS in comparison
with the Synergy stent in a similar lesional setting is associated with
a higher use of resources in the procedure, more radiation and a to
higher TnI release after PCI.
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BACKGROUND In the ASSURE registry, the treatment of de-novo
coronary artery lesions in a real world setting with everolimus-eluting
bioresorbable scaffolds (Absorb, Abbott Vascular, Santa Clara, CA,
USA) was associated with favorable clinical 1-year outcomes. The
current investigation aimed to assess efﬁcacy and safety over a longer
period of time. Here we report on clinical outcomes and angiographic
ﬁndings at 2 years.
METHODS In the prospective, multicenter registry, 183 consecutive
patients received bioresorbable scaffolds at 6 German sites. Two-year
outcomes of equal weight were angina status and freedom from major
adverse cardiovascular events (MACE) and target vessel failure or
revascularization. Quantitative angiography was conducted at follow-
up and in the event of ischemia driven revascularization.
RESULTS Two-year clinical follow-up was completed in 170 (92.9%)
patients. Three (1.8%) patients died for cardiovascular reasons, one
from gastrointestinal bleeding, one from sudden cardiac death, and
one from cardiorespiratory insufﬁciency. Five (2.9%) myocardial in-
farctions due to non-target lesions occurred, and 9 (5.3%) ischemia
driven target lesion revascularizations had become necessary because
of in-scaffold restenosis. One of the participating centers with a 82.1%
(46/56 patients) angiographic follow-up reported on a 20.4% (10/49)
rate of  70% diameter restenosis through 2 years, half of which
associated with symptoms of ischemia. No scaffold thrombosis was
observed. Freedom from MACE was 91.6%  2.1% (95% CI [87.4% -
95,8%]). Ten patients (5.9%) experienced a target vessel failure or
revascularization. Clinical improvement was sustained over two
years, with no substantial change in the rate of angina pectoris since
the 6- and 12-month follow up (16.8% versus 16.9% and 17.3%,
respectively). Quantitative angiographic core lab results from 71 pa-
tients (38.8%) will be available by August 2015.
CONCLUSIONS Two-year ASSURE results suggest that bioresorbable
scaffolds for de-novo coronary artery lesions in daily clinical practice
are safe and effective in the mid term. No scaffold thrombosis was
observed. A considerable number of asymptomatic in-scaffoldrestenoses may have remained undetected. (ClinicalTrials.gov:
NCT01583608)
CATEGORIES CORONARY: Bioresorbable Vascular Scaffolds
KEYWORDS Bioabsorbable scaffolds, Coronary artery disease, Percu-
taneous coronary interventionTCT-507
Edge Vascular Response After Resorption of Everolimus-Eluting
Bioresorbable Vascular Scaffold: A 5-Year Serial Optical Coherence
Tomography Study
Hiroki Tateishi,1 Shimpei Nakatani,2 Yuki Ishibashi,3
Pannipa Suwannasom,4 Maik J. Grundeken,5 Yohei Sotomi,6
Yaping Zeng,7 Erhan Tenekecioglu,8 Susan Veldhof,9
Yoshinobu Onuma,10 Patrick W. Serruys11
1Erasmus MC, Rotterdam, Zuid-Holland; 2ThoraxCenter, Erasmus
Medical Center, Rotterdam, Netherlands; 3Thoraxcenter, Erasmus
University Medical Center, Rotterdam, the Netherlands, Rotterdam,
Netherlands; 4Erasmus Medical Center, Rotterdam, Netherlands;
5Academic Medical Center - University of Amsterdam, Amsterdam,
Netherlands; 6Academic Medical Center - University of Amsterdam,
Amsterdam; 7Erasmus MC, Rotterdam; 8ERASMUS MC, Rotterdam,
South Holland; 9Abott Vascular International BVBA, Diegem, Belgium;
10Thorax Center, Erasmus University, Rotterdam, Netherlands;
11Imperial College London, London, United Kingdom
BACKGROUND This study sought to investigate the edge vascular
response (EVR) after implantation of an everolimus-eluting bio-
resorbable Absorb scaffold using serial optical coherence tomography
(OCT) imaging.
METHODS In the ﬁrst-in-man ABSORB Cohort B trial, 28 patients with
29 lesions underwent truly serial OCT examinations at 4 different time
points (Cohort B1: post-procedure, 6 months, 24 months, and 60
months [n¼13]; B2: post-procedure, 12 months, 36 months, and 60
months [n¼15]) after implantation of an 3.0-mm x 18-mm Absorb
scaffold. A frame-by-frame (200 mm) OCT analysis was performed at
the 5-mm proximal edge, 5-mm distal edge, and 2-mm in-scaffold
margin, whereas the middle 14-mm in-scaffold segment was analyzed
at 1-mm intervals.
RESULTS There was no signiﬁcant change in the lumen area at the
distal edge segment through the entire follow-up period, although
at the distal edge segment the lumen area tended to increase be-
tween post-procedure and 6 months (Cohort B1: 4.94  1.23 mm2
for post-procedure; 5.39  1.83 mm2 for 6 months [p¼0.0520, for
post-procedure vs. 6 months]; 4.95  1.26 mm2 for 24 months; 5.61
 2.08 mm2 for 60 months). In contrast, there was a signiﬁcant
reduction of the lumen in the 2-mm distal margin of the scaffold
between post-procedure and 12 months (at the 1-mm margin: 7.31 
1.02 mm2 vs. 5.66  1.26 mm2, and 2-mm margin: 7.36  1.04 mm2
vs. 5.64  1.30 mm2, respectively, p¼0.001). There was no signiﬁ-
cant change of the lumen in the 2-mm distal margin of the scaffold
between 12 months and 60 months (at the 1-mm margin: 5.66 
1.26 mm2 vs. 4.89  2.02 mm2 [p¼0.116], and 2-mm margin: 5.64 
1.30 mm2 vs. 5.18  1.96 mm2 [p¼0.211]). At the proximal edge
segment the lumen area decreased signiﬁcantly between post-pro-
cedure and 12 months (Cohort B2: 7.20  1.75 mm2 vs. 6.70 
1.53 mm2 p¼0.0168), however between 12 months and 60 months
the lumen remained stable (6.70  1.53 mm2 vs. 6.22  1.83 mm2
p¼0.4623). The 2-mm proximal margin of scaffold segment also
showed a similar change; a signiﬁcant reduction of lumen area at
the ﬁrst 1-mm edge between post-procedure and 12 months (7.49 
1.45 mm2 vs. 6.55  1.08mm2, p¼0.019), however there was no
signiﬁcant change of lumen area at the ﬁrst 1-mm edge between 12
months and 60 months (6.55  1.08 mm2 vs. 5.81  1.22 mm2,
p¼0.508). In the Cohort with 6 months, 24 months, and 60 months
follow-up, no signiﬁcant change was observed in the lumen of the
proximal edge segment (6.37  3.18 mm2 for post-procedure, 6.63 
2.68 mm2 for 6 months, 6.73  2.70 mm2 for 24 months, 6.69 
2.61 mm2 for 60 months).
CONCLUSIONS In the limited number of serial observations by OCT,
some degree of lumen reduction was observed in the proximal edge in
the ﬁrst year after implantation of an Absorb scaffold. However, after
one year the lumen at the both proximal and distal edges remained
stable. The edge effect seems to be a temporary phenomenon,
observed only in the ﬁrst year after implantation.
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